(Press-News.org) A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.
Houston Methodist and a team of researchers from across the country examined the biology of metaplastic breast cancer, comparing it to non-metaplastic triple negative breast cancer. They discovered metaplastic breast cancers typically exhibit two unique signaling pathways in their cell interaction. Researchers were able to disrupt these pathways using a class of inhibitors typically used to treat advanced cancers - phosphoinositide 3 kinase inhibitor (P13K) - in combination with a nitric oxide inhibitor (NOS) typically used to treat septic shock, cardiovascular disease and other conditions. When introduced to the cell, these drugs disrupted these pathways, making the treatment more effective.
A rare and aggressive form of disease, metaplastic breast cancer typically grows faster and is more likely to metastasize or spread to other parts of the body than other breast cancers. It is also more likely to recur after successful initial treatment. Patients with metaplastic breast cancer will often receive the same treatment as a patient with triple negative breast cancer, another aggressive and deadly form of the disease. However, metaplastic breast cancer often does not respond well.
The findings are in the article, “NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression,” and published in Nature Communications, an online journal in the Nature family of publications. The study’s corresponding author is Dr. Jenny Chang, the executive vice president, president and CEO, and chief academic officer at the Houston Methodist Academic Institute. She holds the Ernest Cockrell, Jr. Presidential Distinguished Chair at the Academic Institute and is former director of the Dr. Mary and Ron Neal Cancer Center at Houston Methodist.
“This is a significant finding because it offers a promising therapeutic option for one of the most aggressive and difficult-to-treat subtypes of breast cancer,” said Chang. “We have the potential to improve outcomes for patients who currently face limited treatment options and poor prognoses, marking an important step forward in cancer research and therapy.”
The first author, Dr. Tejaswini Reddy, hopes these findings will help develop a specific care plan for metaplastic cancer patients and improve long-term survival of the disease.
“Our findings highlight a promising therapeutic combination that could hopefully change the landscape of metaplastic breast cancer treatment. Translating this research into a National Cancer Institute-funded clinical trial is crucial to improving outcomes for patients facing this rare and aggressive disease. Moreover, this approach may have broader implications, potentially benefiting patients with other cancers with similar biology,” said Reddy.
The findings of this preclinical study have translated into a National Cancer Institute (NCI)-funded phase 2 clinical trial to help patients with this rare and aggressive malignancy (https://clinicaltrials.gov/study/NCT05660083).
Chang’s collaborators on this study were: Tejaswini Reddy, Akshjot Puri, Liliana Guzman-Rojas, Christoforos Thomas, Wei Qian, Jianying Zhou, Hong Zhao, Bijan Majboubi, Andrian Oo, Young-Jae Cho, Baek Kim, Jose Thaiparambil, Roberto Rosato, Karina Ortega Martinez, Maria Florencia Chevaro, Camila Ayerbe, Noah Giese, David Wink, Stephen Lockett, Stephen Wong, Jeffrey Chang, Savitri Krishnamurthy, Clinton Yam, Stacy Moulder, Hele Piwnica-Worms, and Funda Meric-Bernstam.
This work was supported by NCI grants, the Breast Cancer Research Foundation, CREDO, NIAID, and philanthropic support from Dr. Mary & Ron Neal.
For more information about Houston Methodist, visit our newsroom, On Health and Leading Medicine blogs and follow us on X, Facebook, LinkedIn, Instagram and TikTok.
END
Houston Methodist researchers identify inhibitor drugs to treat aggressive breast cancer
2025-02-03
ELSE PRESS RELEASES FROM THIS DATE:
Skin disease patients show response to targeted treatment
2025-02-03
PHOENIX — Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a chronic inflammatory skin condition of the skin, hair, nails, mouth and genitals. They described their findings in a study published in the Journal of Clinical Investigation that described their first-in-human, phase 2 clinical trial.
The researchers identified unique molecular and cellular changes in the skin with lichen planus, particularly an overactive immune response involving specific types of T cells, a crucial immune system component.
The ...
Tiny copper ‘flowers’ bloom on artificial leaves for clean fuel production
2025-02-03
Tiny copper ‘nano-flowers’ have been attached to an artificial leaf to produce clean fuels and chemicals that are the backbone of modern energy and manufacturing.
The researchers, from the University of Cambridge and the University of California, Berkeley, developed a practical way to make hydrocarbons – molecules made of carbon and hydrogen – powered solely by the sun.
The device they developed combines a light absorbing ‘leaf’ made from a high-efficiency solar cell material called perovskite, with a copper nanoflower catalyst, to convert carbon dioxide into useful molecules. Unlike most metal catalysts, which can only convert CO₂ into single-carbon ...
Cracks in Greenland Ice Sheet grow more rapidly in response to climate change
2025-02-03
Embargoed until 10am GMT UK time (5am US Eastern Time) on Monday 03 February 2025 (Nature Geoscience embargo)
-With pictures-
The Greenland Ice Sheet is cracking open more rapidly as it responds to climate change.
The warning comes in a new large-scale study of crevasses on the world’s second largest body of ice.
Using 3-D surface maps, scientists led by Durham University, UK, found crevasses had significantly increased in size and depth at the fast-flowing edges of the ice sheet over the ...
Computer model helps identify cancer-fighting immune cells key to immunotherapy
2025-02-03
*EMBARGOED FOR RELEASE UNTIL MONDAY, FEB. 3, AT 5 A.M. ET*
Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.
In their study published Feb. 3 in Nature Communications, the team, including first author Zhen Zeng, Ph.D., a bioinformatics research associate at the Kimmel Cancer Center, demonstrated that their three-gene “MANAscore” computer model can identify ...
Keeper or corner?
2025-02-03
Our brain is remarkably flexible in producing different reactions to supposedly comparable situations. The same sensory information can lead to different decisions depending on the behavioral context. One example of this is a penalty kick in soccer: a player can either choose the empty corner of the goal as the target or aim directly at the goalkeeper in the hope that he will jump aside. Both decisions are based on the same perception of the goalkeeper's position, but lead to completely different actions. Neuroscientists at the German Primate Center (DPZ) - Leibniz Institute for Primate Research in Göttingen have investigated how the brain implements this ...
Printable molecule-selective nanoparticles enable mass production of wearable biosensors
2025-02-03
The future of medicine may very well lie in the personalization of health care—knowing exactly what an individual needs and then delivering just the right mix of nutrients, metabolites, and medications, if necessary, to stabilize and improve their condition. To make this possible, physicians first need a way to continuously measure and monitor certain biomarkers of health.
To that end, a team of Caltech engineers has developed a technique for inkjet printing arrays of special nanoparticles that enables the mass production of long-lasting wearable sweat sensors. These sensors could be used to monitor a variety of biomarkers, ...
Mapping the yerba mate genome reveals surprising facts about the evolution of caffeine
2025-02-03
Yerba mate, along with tea and coffee, is one of the world’s most popular caffeinated beverages. Widely consumed in South America, this remarkable plant is rich in diverse, bioactive compounds that contribute many health benefits.
An international group of researchers has mapped the yerba mate genome, providing insights into the biosynthesis of caffeine in yerba mate. This new information provides opportunities for creating plant varieties with new characteristics.
The work, led by the ...
Electricity prices across Europe to stabilise if 2030 targets for renewable energy are met, study suggests
2025-02-03
Hitting the current national 2030 quotas for solar and wind energy could reduce the volatility of electricity markets by an average of 20% across 29 European countries, according to a new study from the University of Cambridge.
The intensity of spikes in power prices are predicted to fall in every country by the end of the decade if commitments to green energy are met, as natural gas dependency is cut.
The UK and Ireland would be the biggest beneficiaries, with 44% and 43% reductions in the severity of electricity price spikes by 2030, compared with last year.
Germany could experience a 31% decline in electricity price ...
Improved treatment timing reduces honey bee losses to Varroa mites
2025-02-03
Honey bee mortality can be significantly reduced by ensuring that treatments for the parasitic Varroa mite occur within specific timeframes, a new study reveals.
The mites—belonging to the species Varroa destructor—feed on the larvae of bees and can destroy colonies if not treated at key points to reduce or remove infestations.
But researchers have found that more than a third of beekeepers surveyed in England and Wales deviate from recommended treatment guidelines, including application windows.
Crucially, they found that beekeepers who mistimed Varroa mite treatments experienced exacerbated colony losses, with the effect occurring ...
CAR-T cells can arm bystander T cells with CAR molecules via trogocytosis
2025-02-03
Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now discovered that CAR molecules can be transferred from the CAR-T cells to other T cells in the tumour microenvironment. The researchers also pinpoint how this transfer is regulated, which may be used to improve the efficacy of CAR-T cell therapy. The study has been published in the journal Science Immunology.
Immune cells have a capacity to exchange cell surface molecules between one another. This exchange is called trogocytosis and may potentially impact the immune response since it allows different proteins to be transferred between cells.
Chimeric antigen ...